Associated Papers
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome.
Pavan A et al.
Translational Lung Cancer Research, 2021
33569305 (PubMed )
Supplement: tlcr-10-01-202-supplementary.pdf
Investigation of PALB2 Mutation and Correlation With Immunotherapy Biomarker in Chinese Non-Small Cell Lung Cancer Patients.
Zhang J et al.
Frontiers in Oncology, 2021
35087742 (PubMed )
Supplement: Table_2.xlsx › Sheet1
USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs.
Malapelle U et al.
Lung Cancer (amsterdam, Netherlands), 2017
Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer.
Pécuchet N et al.
Oncotarget, 2017
26625312 (PubMed )
Supplement: oncotarget-08-23831-s002.xls › Feuil1
Select a paper to view details